Testosterone treatment longer than 1 year shows more effects on functional hypogonadism and related metabolic, vascular, diabetic and obesity parameters (results of the 2-year clinical trial)

References

• Dandona P, Dhindsa S, Chandel A, et al. Hypogonadotropic hypogonadism in men with type 2 diabetes. Postgrad Med. 2009;121(3):45–51.
   PubMed Web of Science ®Google Scholar
• Dandona P, Dhindsa S, Chaudhuri A, et al. Hypogonadotrophic hypogonadism in Type 2 diabetes, obesity and the metabolic syndrome. Curr Mol Med. 2008;8(8):816–828.
   PubMedGoogle Scholar
• Zhang J, Li X, Cai Z, et al. Association between testosterone with type 2 diabetes in adult males, a meta-analysis and trial sequential analysis. Aging Male. 2019;1–12. DOI:10.1080/13685538.2018.1557139
   PubMed Web of Science ®Google Scholar
• LeRoith D. Diabetes in the aging male. Aging Male. 2005;8(3–4):133–134.
   PubMedGoogle Scholar
• Dhindsa S, Ghanim H, Batra M, et al. Hypogonadotropic hypogonadism in men with diabesity. Diabetes Care. 2018;41(7):1516–1525.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1–30.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Morelli A, et al. Treatment of functional hypogonadism besides pharmacological substitution. World J Mens Health. 2020;38(3):256.
   PubMedGoogle Scholar
• Corona G, Rastrelli G, Monami M, et al. Body weight loss reverts obesity-associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol. 2013;168(6):829–843.
   PubMed Web of Science ®Google Scholar
• Grossmann M, Ng Tang Fui M, Cheung AS. Late-onset hypogonadism: metabolic impact. Andrologia. 2019. DOI:10.1111/andr.12705
   Web of Science ®Google Scholar
• Carrageta DF, Oliveira PF, Alves MG, et al. Obesity and male hypogonadism: tales of a vicious cycle. Obes Rev. 2019;20(8):1148–1158.
   PubMed Web of Science ®Google Scholar
• Fernandez CJ, Chacko EC, Pappachan JM. Male obesity-related secondary hypogonadism—pathophysiology, clinical implications and management. Eur Endocrinol. 2019;15(2):83–90.
   PubMedGoogle Scholar
• Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34(7):1669–1675.
   PubMed Web of Science ®Google Scholar
• Deng C, Zhang Z, Li H, et al. Analysis of cardiovascular risk factors associated with serum testosterone levels according to the US 2011–2012 National Health and Nutrition Examination Survey. Aging Male. 2019;22(2):121–128.
   PubMed Web of Science ®Google Scholar
• Mazur A, Westerman R, Werdecker A, et al. Testosterone and type 2 diabetes in men. Aging Male. 2014;17(1):18–24.
   PubMed Web of Science ®Google Scholar
• Ho C-H, Wu C-C, Chen K-C, et al. Erectile dysfunction, loss of libido and low sexual frequency increase the risk of cardiovascular disease in men with low testosterone. Aging Male. 2016;19(2):96–101.
   PubMed Web of Science ®Google Scholar
• Dimopoulou C, Goulis DG, Corona G, et al. The complex association between metabolic syndrome and male hypogonadism. Metab Clin Exp. 2018;86:61–68.
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Miller MG, McWhirter CL, et al. Testosterone concentrations in diabetic and nondiabetic obese men. Diabetes Care. 2010;33(6):1186–1192.
   PubMed Web of Science ®Google Scholar
• Dandona P, Dhindsa S, Chaudhuri A, et al. Hypogonadotrophic hypogonadism in type 2 diabetes. Aging Male. 2008;11(3):107–117.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Saad F, Haider A, et al. The role of the urologist in the prevention and early detection of cardiovascular disease. Arab J Urol. 2011;9(1):57–62.
   PubMedGoogle Scholar
• Kapoor D, Channer KS, Jones TH. Rosiglitazone increases bioactive testosterone and reduces waist circumference in hypogonadal men with type 2 diabetes. Diab Vasc Dis Res. 2008;5(2):135–137.
   PubMed Web of Science ®Google Scholar
• Basu R, Man CD, Campioni M, et al. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care. 2007;30(8):1972–1978.
   PubMed Web of Science ®Google Scholar
• Heufelder AE, Saad F, Bunck MC, et al. Fifty-two week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl. 2009;30(6):726–733.
   PubMedGoogle Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19(1):64–69.
   PubMed Web of Science ®Google Scholar
• Saad F, Caliber M, Doros G, et al. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. Aging Male. 2020;23(1):81–92.
   PubMed Web of Science ®Google Scholar
• Khripun I, Vorobyev S, Belousov I, et al. Influence of testosterone substitution on glycemic control and endothelial markers in men with newly diagnosed functional hypogonadism and type 2 diabetes mellitus: a randomized controlled trial. Aging Male. 2019;22(4):241–249.
   PubMed Web of Science ®Google Scholar
• Haider KS, Haider A, Saad F, et al. Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study. Diabetes Obes Metab. DOI:10.1111/dom.14122
   Web of Science ®Google Scholar
• Yassin A, Haider A, Haider KS, et al. Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: eight-year data from a registry study. Dia Care. 2019;42(6):1104–1111.
   PubMed Web of Science ®Google Scholar
• Vlachopoulos C, Ioakeimidis N, Miner M, et al. Testosterone deficiency: a determinant of aortic stiffness in men. Atherosclerosis. 2014;233(1):278–283.
   PubMed Web of Science ®Google Scholar
• Jones TH, Saad F. The effects of testosterone on risk factors for, and the mediators of, the atherosclerotic process. Atherosclerosis. 2009;207(2):318–327.
   PubMed Web of Science ®Google Scholar
• Antonopoulos AS, Antoniades C. Mechanisms of testosterone deficiency-related endothelial dysfunction: invited commentary for the Hellenic Journal of Cardiology on: Tsikas et al. “Associations between asymmetric dimethylarginine, nitrite-dependent renal carbonic anhydrase activity and plasma testosterone levels in hypogonadal men”. Hellenic J Cardiol. 2018;59(4):207–208.
   PubMed Web of Science ®Google Scholar
• Rezanezhad B, Borgquist R, Willenheimer R, et al. Association between serum levels of testosterone and biomarkers of subclinical atherosclerosis. Aging Male. 2018;21(3):182–186.
   PubMed Web of Science ®Google Scholar
• Mudau M, Genis A, Lochner A, et al. Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovasc J Afr. 2012;23(4):222–231.
   PubMed Web of Science ®Google Scholar
• Crouse JR, Craven TE, Hagaman AP, et al. Association of coronary disease with segment-specific intimal-medial thickening of the extracranial carotid artery. Circulation. 1995;92(5):1141–1147.
   PubMed Web of Science ®Google Scholar
• Muller M, van den Beld AW, Bots ML, et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109(17):2074–2079.
   PubMed Web of Science ®Google Scholar
• Kwon H, Lee D-G, Kang HC, et al. The relationship between testosterone, metabolic syndrome, and mean carotid intima-media thickness in aging men. Aging Male. 2014;17(4):211–215.
   PubMed Web of Science ®Google Scholar
• Demirbag R, Yilmaz R, Ulucay A, et al. The inverse relationship between thoracic aortic intima media thickness and testosterone level. Endocr Res. 2005;31(4):335–344.
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Vorona E, Wenk M, et al. Testosterone administration decreases carotid artery intima media thickness as a marker of impaired vascular integrity in middle-aged overweight men. J Mens Health. 2009;6(3):153–243.
   Web of Science ®Google Scholar
• Wu FCW, Tajar A, Beynon JM, et al.; EMAS Group. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–135.
   PubMed Web of Science ®Google Scholar
• Corona G, Goulis DG, Huhtaniemi I, et al. European Academy of Andrology (EAA) guidelines on investigation, treatment and monitoring of functional hypogonadism in males. Andrology. 2020:1–18. DOI:10.1111/andr.12770
   PubMed Web of Science ®Google Scholar
• Free & Bioavailable Testosterone calculator [Internet]. [cited 2020. Jul 1]. Available from: http://www.issam.ch/freetesto.htm.
   Google Scholar
• Liu J-R, Liu B-W, Yin F-Z. Change in nonhigh-density lipoprotein cholesterol levels in adults with prediabetes. Medicine (Baltimore). 2017;96:e8461.
   PubMed Web of Science ®Google Scholar
• Heinemann LAJ, Saad F, Zimmermann T, et al. The Aging Males’ Symptoms (AMS) scale: update and compilation of international versions. Health Qual Life Outcomes. 2003;1:15.
   PubMedGoogle Scholar
• Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol. 2000;50(5):397–404.
   PubMed Web of Science ®Google Scholar
• Groti K, Žuran I, Antonič B, et al. The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes. Aging Male. 2018;21:1–12.
   PubMed Web of Science ®Google Scholar
• Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154(6):899–906.
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. 2014;11(3):840–856.
   PubMed Web of Science ®Google Scholar
• Dhindsa S, Ghanim H, Batra M, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Dia Care. 2016;39(1):82–91.
   PubMed Web of Science ®Google Scholar
• Blouin K, Boivin A, Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Biol. 2008;108(3–5):272–280.
   PubMed Web of Science ®Google Scholar
• Salman M, Yassin D-J, Shoukfeh H, et al. Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy. Aging Male. 2017;20(1):45–48.
   PubMed Web of Science ®Google Scholar
• Grossmann M, Thomas MC, Panagiotopoulos S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab. 2008;93(5):1834–1840.
   PubMed Web of Science ®Google Scholar
• Francomano D, Bruzziches R, Barbaro G, et al. Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Invest. 2014;37(4):401–411.
   PubMed Web of Science ®Google Scholar
• Yassin A, Doros G. Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes. 2013;3(3–4):73–83.
   PubMedGoogle Scholar
• Hoyos CM, Killick R, Yee BJ, et al. Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo-controlled trial. Clin Endocrinol. 2012;77(4):599–607.
   PubMed Web of Science ®Google Scholar
• Grundy SM, Arai H, Barter P, et al. An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia-full report. J Clin Lipidol. 2014;8(1):29–60.
   PubMed Web of Science ®Google Scholar
• Mazo E, Gamidov S, Sotnikova E. Effects of different treatments on endothelial function in patients with erectile dysfunction and hypogonadism. Ter Arkh. 2008;80:59–63.
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med. 2010;7(10):3495–3503.
   PubMed Web of Science ®Google Scholar
• Basaria S, Harman S, Travison TG, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314(6):570–581.
   PubMed Web of Science ®Google Scholar
• Kelly DM, Jones TH. Testosterone: a vascular hormone in health and disease. J Endocrinol. 2013;217(3):R47–R71.
   PubMed Web of Science ®Google Scholar
• Tremellen K, McPhee N, Pearce K. Metabolic endotoxaemia related inflammation is associated with hypogonadism in overweight men. Basic Clin Androl. 2017;27:5.
   PubMed Web of Science ®Google Scholar
• Laaksonen DE, Niskanen L, Punnonen K, et al. Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol. 2003;149:601–608.
   PubMed Web of Science ®Google Scholar
• Soisson V, Brailly-Tabard S, Helmer C, et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas. 2013;75(3):282–288.
   PubMed Web of Science ®Google Scholar
• Bhatia V, Chaudhuri A, Tomar R, et al. Low testosterone and high C-reactive protein concentrations predict low hematocrit in type 2 diabetes. Diabetes Care. 2006;29(10):2289–2294.
   PubMed Web of Science ®Google Scholar
• Bobjer J, Katrinaki M, Tsatsanis C, et al. Negative association between testosterone concentration and inflammatory markers in young men: a nested cross-sectional study. PloS One. 2013;8(4):e61466.
   PubMed Web of Science ®Google Scholar
• Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf). 2010;73(5):602–612.
   PubMed Web of Science ®Google Scholar
• Traish AM, Haider A, Doros G, et al. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014;68(3):314–329.
   PubMed Web of Science ®Google Scholar
• Corrales JJ, Almeida M, Burgo R, et al. Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging type-2 diabetic men with partial androgen deficiency. J Endocrinol. 2006;189(3):595–604.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89(7):3313–3318.
   PubMed Web of Science ®Google Scholar
• Haider A, Gooren LJG, Padungtod P, et al. Improvement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with parenteral testosterone undecanoate. Exp Clin Endocrinol Diabetes. 2010;118(3):167–171.
   PubMed Web of Science ®Google Scholar
• Kapoor D, Clarke S, Stanworth R, et al. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2007;156(5):595–602.
   PubMed Web of Science ®Google Scholar
• Mohamad N-V, Wong SK, Wan Hasan WN, et al. The relationship between circulating testosterone and inflammatory cytokines in men. Aging Male. 2019;22(2):129–140.
   PubMed Web of Science ®Google Scholar
• Grossmann M. Testosterone and glucose metabolism in men: current concepts and controversies. J Endocrinol. 2014;220:37–55.
   PubMed Web of Science ®Google Scholar
• Goldman AL, Bhasin S, Wu FCW, et al. A reappraisal of Testosterone’s Binding in Circulation: physiological and clinical implications. Endocr Rev. 2017;38(4):302–324.
   PubMed Web of Science ®Google Scholar